#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Malignant neoplasm of choroid Haemolytic uraemic syndrome Glioma Rosai-Dorfman syndrome Amyloidosis Cognitive disorder Gastrointestinal disorder Pleural mesothelioma malignant Wolfram syndrome Glomerulonephritis membranoproliferative Wiskott-Aldrich syndrome Factor VIII deficiency Thalassaemia beta Aplastic anaemia Adrenogenital syndrome More trials…

    Learn about Rare Diseases

    Pulmonary sarcoidosis – Treatment Metachromatic leukodystrophy – Treatment Biotinidase deficiency – Diagnostics Mucopolysaccharidosis III – Life with Disease Adrenogenital syndrome – Treatment Glomerulonephritis membranous – Basic Information Hereditary hypophosphataemic rickets – Diagnostics Pituitary-dependent Cushing’s syndrome – Basic Information Hereditary ataxia – Life with Disease Gastrointestinal stromal tumour – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Calcium Levofolinate Ixazomib CHONDROITIN SULFATE SODIUM Bms-986435 FG001 Montelukast Fludarabine Phosphate Ph. Eur. Ep0042 AAV9-CTNT-COBAG3 Tremelimumab VG801-2 AZD6234 Regorafenib Efpegerglucagon ASP3082 Venglustat Remimazolam Abacavir Sulfate SAROGLITAZAR HEMIMAGNESIUM ALPROSTADIL More therapies…

    Learn about Your Condition

    Endometrial cancer Heparin resistance Eosinophilic oesophagitis Heart disease congenital Erdheim-Chester disease Haematological malignancy Embolism Glioblastoma Bladder cancer Type 1 diabetes mellitus Malignant melanoma Tendon disorder Myxofibrosarcoma Eyelid ptosis Propionic acidaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

    Recruiting

    4 1
    Investigated Diseases:
    • Cachexia
    Investigated Drugs:
    • VISUGROMAB
    Bulgaria Czechia France Germany Ireland Italy +5

  • A Study to Find a Safe Dose of TD001 for Patients with Metastatic Castration-Resistant Prostate Cancer that Expresses PSMA

    Recruiting

    2 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    France Spain

  • Long-term study of bitopertin safety and effectiveness in patients with erythropoietic protoporphyria or X-linked protoporphyria

    Recruiting

    3 1 1
    Belgium France Germany Ireland Italy The Netherlands +3

  • Testing 68Ga-NOTA-ABSCINT-HER2 Imaging to Predict Treatment Response in Patients with HER2-Positive Early Breast Cancer Receiving Chemotherapy

    Recruiting

    1 1 1
    Investigated Drugs:
    • 68Ga-Nota-Abscint-Her2
    France

  • A study testing lenadogene nolparvovec gene therapy injections into the eye to improve vision in patients with ND4 Leber Hereditary Optic Neuropathy

    Recruiting

    2 1 1
    Investigated Diseases:
    • Hereditary optic atrophy
    France

  • A Study of Upadacitinib for Adults with Moderate to Severe Atopic Dermatitis Who Did Not Respond Well Enough to Dupilumab Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Dupilumab
    • Upadacitinib
    Italy Romania Spain
Previous Page
1 … 80 81 82 83 84 … 1,646
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!